Sun Pharma shares dip 3% as US FDA conducts inspection at Baska facility; check details

The inspection was conducted from September 8, 2025, to September 19, 2025, the pharma major said. The US FDA has subsequently determined that the inspection classification status of this facility is Official Action Indicated (OAI).

“We continue to manufacture and supply approved products from the facility to the US market. We will work with the regulator to achieve fully compliant status,” Sun Pharma said in a regulatory filing.

Sun Pharma share price

At 11:45 AM, Sun Pharma shares were trading at ₹1,746.70 apiece on the National Stock Exchange, declining 2.58%.

In the last five trading sessions, the stock has lost over 3%, while for the 6-month period, the shares have jumped 6%. Since the beginning of 2025, Sun Pharma shares have fallen 8%.

Shares of the firm had hit a 52-week high of ₹1,919 on December 31, 2024, and a 52-week low of ₹1,548 on September 26, 2025.

The company has a total market capitalisation of ₹4.19 lakh crore, according to data on the NSE.

Sun Pharma Q2 earnings

Sun Pharma’s consolidated net profit rose 2.5% to ₹3,118 crore in the second quarter of the fiscal year (Q2 FY26) as compared to ₹3,040 crore reported in the same period of the previous fiscal year.

The pharma major's total revenue from operations jumped 9% on a year-on-year (YoY) basis to ₹14,478 crore in the July to September quarter as against ₹13,291 crore seen in Q2 FY25.

Its operating profit, also known as earnings before interest, taxes, depreciation, and amortisation (EBITDA), surged 15% to ₹4,527 crore as against ₹3,939 crore in the corresponding period last year. Its EBITDA margin also expanded to 31.2%, in contrast to 29.6% in the year-ago period.

Sun Pharma is a speciality generics company with operations across innovative medicines, generics and consumer healthcare. It is the largest pharmaceutical company in India and has a notable presence in the US and global emerging markets. Around 20% of its sales come from its Innovative Medicines segment, which includes products in dermatology, ophthalmology, and onco-dermatology.

The company operates through vertically integrated facilities and supplies medicines to over 100 countries. Its manufacturing network spans six continents, and its workforce includes professionals from more than 50 countries.